Forecasting essential childhood cancer drug need: An innovative model‐based approach

Background Childhood cancer outcomes in low‐income and middle‐income countries have not kept pace with advances in care and survival in high‐income countries. A contributing factor to this survival gap is unreliable access to essential drugs. Methods The authors created a tool (FORxECAST) capable of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2021-08, Vol.127 (16), p.2990-3001
Hauptverfasser: Hughes, Terence M., Empringham, Brianna, Wagner, Anita K., Ward, Zachary J., Yeh, Jennifer, Gupta, Sumit, Frazier, A. Lindsay, Denburg, Avram E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Childhood cancer outcomes in low‐income and middle‐income countries have not kept pace with advances in care and survival in high‐income countries. A contributing factor to this survival gap is unreliable access to essential drugs. Methods The authors created a tool (FORxECAST) capable of predicting drug quantity and cost for 18 pediatric cancers. FORxECAST enables users to estimate the quantity and cost of each drug based on local incidence, stage breakdown, treatment regimen, and price. Two country‐specific examples are used to illustrate the capabilities of FORxECAST to predict drug quantities. Results On the basis of domestic public‐sector price data, the projected annual cost of drugs to treat childhood cancer cases is 0.8 million US dollars in Kenya and 3.0 million US dollars in China, with average median price ratios of 0.9 and 0.1, respectively, compared with costs sourced from the Management Sciences for Health (MSH) International Medical Products Price Guide. According to the cumulative chemotherapy cost, the most expensive disease to treat is acute lymphoblastic lymphoma in Kenya, but a higher relative unit cost of methotrexate makes osteosarcoma the most expensive diagnosis to treat in China. Conclusions FORxECAST enables needs‐based estimates of childhood cancer drug volumes to inform health system planning in a wide range of contexts. It is broadly adaptable, allowing decision makers to generate results specific to their needs. The resultant estimates of drug need can help equip policymakers and health governance institutions with evidence‐informed data to advance innovative procurement strategies that drive global improvements in childhood cancer drug access. A pediatric‐specific tool (FORxECAST) was created that estimates drug quantity and cost for 18 cancers. The results enable evidence‐based forecasting of childhood cancer drug quantity and cost to inform health system planning in a wide range of countries.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.33568